Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with 4T's Score greater than or equal to 4.~Exclusion Criteria:~* Require ongoing anticoagulant therapy for a mechanical heart valve.~* Severe renal insufficiency (CrCl\<30 ml/min)~* Hepatic disease (including Child-Pugh B and C) associated with coagulopathy and a clinically relevant bleeding risk~* Inability to take oral medications.~* Ongoing requirement for systemic treatment with azole-antimycotics (except fluconazole) or HIV-protease inhibitors or strong CYP3A4 inducers~* Clinically significant active bleeding or lesions at increased risk for bleeding within the last 6 months~* Platelet count less than 80 and an ongoing need for antiplatelet therapy may be excluded at the discretion of the investigator~* Pregnant or a woman of child-bearing potential not using an adequate birth control method~* Hypersensitivity to rivaroxaban or to any ingredient in the formulation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.

Based on this trial design, predict the completion outcome and termination type (if applicable).